The U.S. Food and Drug Administration (FDA) has published a consumer page stating that it has not authorized clear aligners sold directly to consumers without a prescription and supervision by a dentist or orthodontist. The agency lists complications it has received reports about, separates "FDA-registered" from "FDA-authorized," and stresses in-person examination and follow-up. The notice is a U.S. regulatory communication, but it gives Canadian practices a clear, citable reference point for conversations with patients who are weighing mail-order treatment.
As of October 2026, direct-to-consumer orthodontics has a new piece of regulatory language attached to it. The FDA's consumer page on clear dental aligners, marked as current as of September 9, 2026, states plainly: "The FDA has not authorized clear aligners that are marketed directly to consumers without supervision by a dentist or orthodontist." ADA News reported on the page on October 1, 2026, and the trade publication Orthodontic Products covered it on September 17, 2026, alongside a response from the American Association of Orthodontists (AAO).
For dental professionals in Toronto and across the Greater Toronto Area, the practical question is not whether a U.S. agency's page changes Canadian law. It does not. The question is what the page says, what it does not say, and how your practice can use it when a patient in Mississauga, Markham or Scarborough arrives with a box of aligners and a problem.
What the FDA Page Says
The FDA describes clear aligners as "a series of custom-made, removable plastic trays designed to gradually move teeth into a desired position" and states that they are "available by prescription from a licensed practitioner, such as a dentist or orthodontist." The agency says it "reviews and authorizes clear aligners before being marketed and sold in the United States."
The central sentence is the one about supervision. According to the FDA, clear aligners "are prescription devices, meaning they are only safe to use under the supervision of a licensed practitioner." The page adds that "in-person examination by a dentist or orthodontist can help lower the risks of uneven bite, unintended tooth movement, pain, and tooth loss," and that periodic in-person visits after treatment begins "can help ensure that your teeth are moving safely and as planned."
Teledentistry is acknowledged, not rejected
The page does not dismiss remote care. It notes that some treatment plans may include remote monitoring and virtual visits, and says: "While virtual visits can be a useful part of dental care, periodic, in-person visits to see a dentist or orthodontist can help reduce the risks of an uneven bite, unintended tooth movement, pain, and tooth loss, and ensure your treatment is progressing appropriately." The emphasis is on in-person care as a component of supervision, not on banning virtual check-ins.
Reported complications
The FDA states that it has received reports involving non-authorized direct-to-consumer clear aligners in which patients experienced:
- New or worsening dental pain
- Jaw pain
- Bite problems
- Worsening tooth misalignment
- New gaps between teeth
The page does not give a count of reports, and it should not be read as a measure of how often these problems occur. It is a list of reported complication types, paired with an instruction that patients experiencing new or worsening symptoms should contact a dentist or orthodontist for an evaluation.
"FDA-Registered" Is Not "FDA-Authorized"
One of the most useful parts of the page for chairside conversations is a short definitional note. "Some companies may say they are FDA-registered, but this is not the same as FDA-authorized," the agency says. According to the FDA, registration means a manufacturer "has simply listed its facility and products with the FDA," whereas authorization means "the FDA has actively reviewed the specific product and cleared or approved it for public use."
The FDA tells U.S. consumers they can ask their dentist or orthodontist about the product being used, or search the FDA's 510(k) database using the product code NXC to check whether a product has received FDA authorization.
That distinction matters because marketing copy often blurs it. A patient who has seen "FDA-registered" on a website may reasonably assume the product was reviewed. The FDA's own wording now gives you a neutral, non-commercial source to point to.
What the FDA Recommends to Patients
For people considering clear aligners, the FDA's page lists five recommendations:
- Receive an evaluation by a dentist or orthodontist, preferably in person, to determine whether clear aligners are appropriate.
- Discuss the benefits and risks with the dentist or orthodontist.
- Follow instructions regarding wear time and follow-up visits.
- Attend recommended appointments during treatment.
- Report pain, bite problems or other unexpected symptoms to the dentist or orthodontist.
The page also lists risks and limitations that apply to clear aligners generally, not only to direct-to-consumer products. These include that aligners may not effectively treat more complex orthodontic conditions, can be lost or damaged, may cause temporary speech changes, and may cause irritation or allergic reactions in some patients. The FDA also notes that existing crowns, fillings and implants "may loosen or become dislodged and require repair or replacement," and lists swelling and laceration as possible adverse events.
Pro Tip: Add the FDA's five patient recommendations, paraphrased in your own words, to the consent discussion notes your team uses for aligner consultations. It gives every clinician the same neutral checklist to walk through.
How the Profession Responded
According to Orthodontic Products, the AAO described the FDA page as a milestone in its advocacy on mail-order orthodontics. "This announcement reflects years of sustained advocacy by the AAO and its members to elevate patient health and safety concerns associated with clear aligner treatment provided without appropriate clinical oversight," AAO president Mike Durbin said in a release quoted by the publication.
The same report says the AAO met with the FDA in July 2024 to share clinical examples of harm linked to mail-order aligners, and that in September 2025 an AAO delegation delivered a letter signed by 1,745 members documenting complications from direct-to-consumer treatment. Orthodontic Products also connected the FDA update to the proposed Oversight of Responsible Teledentistry for Healthy Outcomes (ORTHO) Act (HR 9829), introduced by U.S. Representative Brian Babin, which it describes as legislation that would require an in-person dental examination and a review of diagnostic records, including X-rays, before orthodontic treatment begins. That bill is a U.S. proposal and has no bearing on Canadian practice.
What This Means for Canadian Practices
The FDA regulates the U.S. market. Its consumer page does not change the status of any product in Canada, and it should not be described to patients as a Canadian ruling.
In Canada, Health Canada's Medical Devices Bureau is the federal regulator responsible for licensing medical devices under the Food and Drugs Act and its regulations. Health Canada maintains the Medical Devices Active Licence Listing (MDALL), which it describes as a database of all licensed Class II, III and IV medical devices offered for sale in Canada. Two caveats apply when you search it. First, Health Canada states that Class I devices do not require a medical device licence and do not appear in the listing. Second, you need to know which class a given product falls into before an empty search result means anything.
Pro Tip: When a patient asks about a specific aligner brand, ask the supplier or manufacturer for the device's Canadian classification and, where applicable, its licence number, then confirm it in MDALL. If the product is not where it should be, treat that as a question to resolve before the patient continues.
When a patient arrives mid-treatment
Some GTA practices may see patients who started orthodontic treatment elsewhere, including through mail-order companies. The FDA page offers a framework you can mirror without overstating anything:
- Examine and document. Record the symptoms the patient reports and your clinical findings, along with the product name and manufacturer.
- Explain in neutral terms. The FDA's language ("the lack of appropriate professional supervision may increase the risk of complications") is measured. Use the same tone. A patient who feels judged for a purchase may be less inclined to return for follow-up.
- Report problems. Health Canada states that anyone can report a side effect or medical device problem, and that reports help it identify safety signals. The FDA, for its part, asks that serious adverse events be reported to both the agency and the manufacturer.
Regulatory guidance to follow in Ontario
Ontario dentists considering any form of remote orthodontic monitoring should review the Royal College of Dental Surgeons of Ontario (RCDSO) Standard of Practice on Virtual Care, approved by Council in December 2023, before changing their workflow. The standard defines virtual care (also known as teledentistry) and sets out requirements for providing it, including assessing whether virtual care is appropriate, obtaining consent, protecting privacy and recordkeeping. The FDA's view that in-person visits remain part of safe supervision is consistent with a cautious approach, but your obligations in Ontario are set by the RCDSO, not by a U.S. agency.
EBIKO Dental will continue monitoring regulatory developments that affect orthodontic care and will report on any Canadian guidance that follows. For supplies and clinical resources, visit EBIKO Dental.
Sources
- U.S. FDA: Clear Dental Aligners (content current as of 09/09/2026)
- ADA News: FDA warns public about unauthorized direct-to-consumer clear aligners (October 1, 2026)
- Orthodontic Products: AAO Welcomes FDA Clear Aligner Guidance Highlighting Direct-to-Consumer Risks
- Health Canada: Medical Devices Active Licence Listing (MDALL)
- RCDSO: Standard of Practice, Virtual Care (approved December 2023)
- Health Canada: Report a side effect of a health product, drug or medical device
Frequently Asked Questions
Q: Has the FDA banned direct-to-consumer clear aligners?
The FDA's page does not use the word "ban." It states that the agency has not authorized clear aligners that are sold directly to consumers without a prescription and supervision by a dentist or orthodontist, and that the lack of professional supervision may increase the risk of complications.
Q: Does the FDA warning apply in Canada?
No. The FDA regulates the U.S. market. In Canada, Health Canada licenses medical devices, and its MDALL database lists licensed Class II, III and IV devices. Class I devices do not appear in MDALL, so confirm a product's class and licence status with the manufacturer.
Q: What is the difference between FDA-registered and FDA-authorized?
According to the FDA, registration means a manufacturer has listed its facility and products with the agency, while authorization means the FDA has reviewed the specific product and cleared or approved it for public use. The FDA says companies claiming registration are not making the same claim as authorization.